Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HTBX,135844018,25397300,,,-7623140,-836366,-7532178,4767645,-2867603,-7635248,-7635248,,,,,,0,538645,8173893,3406248,12108,,-7623140,-7532178,275618780,8010119,137296356,5866000,93529,144470109,5027,-138179663,3604161,1452338,-147788,6007201,31156747,3046143,-147788,3132243,133878327,100899984,103232,792545,-203859.0,-769326.0,-567257.0,-30171.0,25643188.0,282662.0,26331543.0,20224857.0,-1088.0,-4849986.0,101803.0,73814.0,-658184.0,2993239.0,-363398.0,,130832184,en-US,US,EQUITY,True,Delayed Quote,7.44,1630526403,0.21000004,7.29,7.47,6.9709,509133,USD,NCM,188955920,-14400000,False,False,PRE,2,2.9045649,6.9709 - 7.47,us_market,0,"Heat Biologics, Inc.",7.23,0.0,0.0,9,8,finmb_79723070,NasdaqCM,"Heat Biologics, Inc.",USD,918751,252614,2.2200003,0.42528743,5.22 - 17.0,-9.559999,-0.5623529,5.22,17.0,1607644800,1620199800,1628166600,1628512200,-1.365,-1.17,-1.18,-6.305085,5.462,6.477714,0.962286,0.14855333,7.0760145,0.36398554,0.051439345,-6.3589745,1.3621384,15,America/New_York,EDT,0.28,,,17.0,5.22,6.48,7.08,918.75k,252.61k,25.4M,,24.16M,4.09%,12.04%,2.34M,6.47,9.68%,9.25%,2.61M,,,,,,0.00%,"Dec 10, 2020",,1:7,"Dec 10, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,060.44%",-18.80%,-33.90%,2.58M,0.13,-40.30%,-9.99M,-27.04M,-27.29M,-1.37,,132.06M,5.23,1.76M,1.29,43.95,5.46,-21.09M,-14.21M,Value,27560,Healthcare,39,"Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",Morrisville,919 240 7133,NC,1609372800,United States,http://www.heatbio.com,86400,627 Davis Drive,Biotechnology,Suite 400
t-1,HTBX,114786989,25397300,,,-6554718,-745404,-6451592,3283021,-3589737,-6872758,-6872758,,,,,,0,603192,7475950,4192929,318040,,-6554718,-6451592,247048349,8700719,116239327,5866000,603717,124194642,4519,-130647485,3581948,1452338,-166056,5988779,10931890,3656895,-166056,2959338,113794187,100842438,177239,1051764,-8344471.0,-269631.0,-8361142.0,-30059.0,922705.0,-225710.0,1076734.0,-13876193.0,4997.0,-6442753.0,90529.0,32888.0,-26918.0,380763.0,-16671.0,-97052.0,110137292,en-US,US,EQUITY,True,Delayed Quote,7.44,1630526403,0.21000004,7.29,7.47,6.9709,509133,USD,NCM,188955920,-14400000,False,False,PRE,2,2.9045649,6.9709 - 7.47,us_market,0,"Heat Biologics, Inc.",7.23,0.0,0.0,9,8,finmb_79723070,NasdaqCM,"Heat Biologics, Inc.",USD,918751,252614,2.2200003,0.42528743,5.22 - 17.0,-9.559999,-0.5623529,5.22,17.0,1607644800,1620199800,1628166600,1628512200,-1.365,-1.17,-1.18,-6.305085,5.462,6.477714,0.962286,0.14855333,7.0760145,0.36398554,0.051439345,-6.3589745,1.3621384,15,America/New_York,EDT,0.28,,,17.0,5.22,6.48,7.08,918.75k,252.61k,25.4M,,24.16M,4.09%,12.04%,2.34M,6.47,9.68%,9.25%,2.61M,,,,,,0.00%,"Dec 10, 2020",,1:7,"Dec 10, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,060.44%",-18.80%,-33.90%,2.58M,0.13,-40.30%,-9.99M,-27.04M,-27.29M,-1.37,,132.06M,5.23,1.76M,1.29,43.95,5.46,-21.09M,-14.21M,Value,27560,Healthcare,39,"Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",Morrisville,919 240 7133,NC,1609372800,United States,http://www.heatbio.com,86400,627 Davis Drive,Biotechnology,Suite 400
t-2,HTBX,120088200,25397300,,,-8916433,-642278,-8851609,6579193,-2322931,-8902124,-8902124,,,,,,0,849732,9751856,3172663,-14309,,-8916433,-8851609,245740939,8812058,121540538,5866000,1166481,129710318,31402,-124195893,3447672,1452338,-35910,5995505,24808083,3802364,-35910,3120728,119141747,92501019,212141,753872,-66202070.0,-738066.0,-66311970.0,-30171.0,75954458.0,-794433.0,79973784.0,4139842.0,1006.0,-5503652.0,88629.0,-181350.0,-3989155.0,4973177.0,-109900.0,-97052.0,115339383,en-US,US,EQUITY,True,Delayed Quote,7.44,1630526403,0.21000004,7.29,7.47,6.9709,509133,USD,NCM,188955920,-14400000,False,False,PRE,2,2.9045649,6.9709 - 7.47,us_market,0,"Heat Biologics, Inc.",7.23,0.0,0.0,9,8,finmb_79723070,NasdaqCM,"Heat Biologics, Inc.",USD,918751,252614,2.2200003,0.42528743,5.22 - 17.0,-9.559999,-0.5623529,5.22,17.0,1607644800,1620199800,1628166600,1628512200,-1.365,-1.17,-1.18,-6.305085,5.462,6.477714,0.962286,0.14855333,7.0760145,0.36398554,0.051439345,-6.3589745,1.3621384,15,America/New_York,EDT,0.28,,,17.0,5.22,6.48,7.08,918.75k,252.61k,25.4M,,24.16M,4.09%,12.04%,2.34M,6.47,9.68%,9.25%,2.61M,,,,,,0.00%,"Dec 10, 2020",,1:7,"Dec 10, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,060.44%",-18.80%,-33.90%,2.58M,0.13,-40.30%,-9.99M,-27.04M,-27.29M,-1.37,,132.06M,5.23,1.76M,1.29,43.95,5.46,-21.09M,-14.21M,Value,27560,Healthcare,39,"Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",Morrisville,919 240 7133,NC,1609372800,United States,http://www.heatbio.com,86400,627 Davis Drive,Biotechnology,Suite 400
t-3,HTBX,46260986,25397300,,,-4536818,-577454,-4454430,1801674,-2197632,-3999306,-3999306,,,,,,0,593165,4592471,2790797,-537512,,-4536818,-4454430,163007558,11017161,47713324,5866000,3901924,58153031,22006,-115344284,3181212,1452338,28044,5988905,20668241,6217875,28044,3110617,47601171,26312039,26967,779642,-20510720.0,-1004291.0,-20691488.0,-30171.0,24900421.0,-131298.0,25570418.0,-70535.0,14635.0,-4294103.0,86395.0,117957.0,-639826.0,1091564.0,-180768.0,-97052.0,41383296,en-US,US,EQUITY,True,Delayed Quote,7.44,1630526403,0.21000004,7.29,7.47,6.9709,509133,USD,NCM,188955920,-14400000,False,False,PRE,2,2.9045649,6.9709 - 7.47,us_market,0,"Heat Biologics, Inc.",7.23,0.0,0.0,9,8,finmb_79723070,NasdaqCM,"Heat Biologics, Inc.",USD,918751,252614,2.2200003,0.42528743,5.22 - 17.0,-9.559999,-0.5623529,5.22,17.0,1607644800,1620199800,1628166600,1628512200,-1.365,-1.17,-1.18,-6.305085,5.462,6.477714,0.962286,0.14855333,7.0760145,0.36398554,0.051439345,-6.3589745,1.3621384,15,America/New_York,EDT,0.28,,,17.0,5.22,6.48,7.08,918.75k,252.61k,25.4M,,24.16M,4.09%,12.04%,2.34M,6.47,9.68%,9.25%,2.61M,,,,,,0.00%,"Dec 10, 2020",,1:7,"Dec 10, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-1,060.44%",-18.80%,-33.90%,2.58M,0.13,-40.30%,-9.99M,-27.04M,-27.29M,-1.37,,132.06M,5.23,1.76M,1.29,43.95,5.46,-21.09M,-14.21M,Value,27560,Healthcare,39,"Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.",Morrisville,919 240 7133,NC,1609372800,United States,http://www.heatbio.com,86400,627 Davis Drive,Biotechnology,Suite 400
